pixantrone

Pixuvri®

Pages intended for UK practising Healthcare Professionals only

Therapeutic indications1

Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy Conditional marketing authorisation in European Union: Annual renewal.  Pixantone is already included and recommended in national and international guidelines1,2

  • Included in ESMO DLBCL guidelines1
    • Level of recommendation: 11, C*
  • Recommended by NICE2

 

Summary of Product Characteristics

Package Information Leaflet

Prescribing Information

 

1. References Tily H et al. Ann Oncol 2015; 26 (suppl 5) v116-v125

2. www.nice.org.uk/guidance/TA306

 

UK17WEB0004 DoP: June 2017